DMK Pharmaceuticals Corporation
CY3B
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 30.36% | 36.71% | 38.57% | 42.22% | 41.86% |
| Total Depreciation and Amortization | -56.90% | -33.32% | -13.99% | 3.33% | -10.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,673.54% | 6.34% | -78.51% | -97.71% | -98.53% |
| Change in Net Operating Assets | 781.60% | 341.79% | 113.27% | 88.16% | 85.52% |
| Cash from Operations | 69.86% | 60.58% | 48.75% | 31.40% | 14.49% |
| Capital Expenditure | 88.79% | 60.48% | 22.64% | 44.38% | 15.49% |
| Sale of Property, Plant, and Equipment | 190.57% | 190.57% | 190.57% | 190.57% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -131.59% | -166.45% | -138.85% | -25.33% | 3,736.77% |
| Cash from Investing | -35.40% | -47.97% | 25.71% | 1,131.93% | 620.18% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 166.49% | -99.98% | -- | -- | -94.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -94.74% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 153.28% | 232.15% | 230.57% | 99.72% | -54.29% |
| Cash from Financing | 4,313.09% | 246.83% | 245.03% | -99.47% | -99.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 16.16% | -117.44% | -- | -- | -- |
| Net Change in Cash | 116.02% | 73.71% | 63.08% | -234.16% | -257.37% |